NRW.Venture

What NRW.Venture does

NRW.Venture is the venture-capital arm of NRW.BANK (Förderbank für Nordrhein-Westfalen), the state-owned development bank of North Rhine-Westphalia, Germany. It operates as a public-sector risk-capital (Wagniskapital) fund that provides equity financing to early-stage startups based in NRW, with the explicit mandate of supporting the development and commercialization of innovative technologies and business models. The fund targets founders who lack easy access to conventional bank loans, and its portfolio to date spans biotech (iDEL Therapeutics, Dortmund — tumor-cytosol cancer therapeutics) and legal-tech AI (JUPUS GmbH, Cologne).

NRW.Venture does not develop proprietary technology itself; it is a financing vehicle and is operationally embedded within NRW.BANK's broader Gründer (Founders) ecosystem, which also provides advisory services, the NRW.BANK.Innovationspartner program, and connections to regional innovation partners. Distribution is institution-led: deal flow originates from NRW.BANK's website, partner referrals, and direct outreach, with investments typically executed as co-investments alongside specialist lead VCs rather than as solo rounds.

Economically, NRW.Venture generates returns via equity stakes in portfolio companies, with value realized through exits (acquisitions, IPOs) or portfolio appreciation over time. It does not sell a product or charge per-deal fees in the conventional sense; rather, its financial model is anchored in long-horizon venture returns subsidized by state-backed capital. The fund benefits from the state's institutional guarantee and favorable refinancing conditions available to NRW.BANK, enabling it to take positions in technology-risk investments that purely private capital may find uneconomic.

Name

NRW.Venture

Legal name

NRW.BANK

Website

https://nrwbank.de

Company type

Private

Operating status

Operating

Short description

NRW.Venture is the venture-capital arm of NRW.BANK, the state development bank of North Rhine-Westphalia, Germany. It provides risk-capital equity financing to early-stage startups in NRW developing innovative technologies and business models, typically as a co-investor alongside specialist venture funds.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259), Other Financial Vehicles (52599)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

Keywords

• Venture capital funding
• Early-stage equity investment
• Startup growth financing
• Risk capital investment
• Innovation financing

Headquarters

HQ city

Düsseldorf

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Capital Gains / Investment Returns: NRW.Venture generates returns through equity stakes in early-stage startups. As a development bank fund, it invests in startups in North Rhine-Westphalia to support innovation, with returns realized through exits (acquisitions, IPOs) or ongoing portfolio value appreciation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

NRW.Venture is a venture capital fund operated by NRW.BANK that provides risk capital (Wagniskapital) to early-stage startups headquartered in North Rhine-Westphalia (NRW), Germany. It invests in companies developing innovative technologies and business models, participating in rounds such as seed and Series A financings. Examples of portfolio activity include a €3 million Series A in JUPUS GmbH and a €9 million seed round in iDEL Therapeutics.

Product overview

NRW.Venture is a venture capital program operated by NRW.BANK (the development bank for North Rhine-Westphalia, Germany). It is not a standalone tech product but rather a public-sector financing instrument that provides risk capital (Wagniskapital) to startups and early-stage companies in North Rhine-Westphalia. The program supports startups in developing and marketing innovative technologies and business models, as well as rapid business expansion. NRW.Venture functions as part of NRW.BANK's broader startup financing ecosystem, which includes various funding programs and advisory services.

Differentiator

Problem solved

Functional benefit

Products and services

• NRW.Venture Fund

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• Bayern Kapital: Bavaria's state-backed venture capital firm. Highly comparable to NRW.Venture as a regional public-sector VC arm, investing in early-stage Bavarian startups with state institutional backing and a co-investment model.
• KfW Capital: Germany's federal development-bank venture capital arm, run by KfW. Direct comparable to NRW.Venture in structure and mandate — public-sector VC investing in German startups — but operates at federal rather than state level with a much larger fund-of-funds mandate.
• coparion: German VC backed by public-bank-style institutional investors (including KfW Capital) investing in Series A German startups. Comparable in stage, geography, and the public-bank-capitalized VC structure.
• bmp Ventures: Long-established German early-stage VC with operations in NRW and beyond. Comparable as a generalist early-stage investor in German tech and life sciences, often syndicating with public-bank funds.
• Gründerfonds Ruhr: Regional VC fund focused on startups in the Ruhr area of North Rhine-Westphalia. Already a documented co-investment partner of NRW.Venture (iDEL Therapeutics round), making it both a peer and collaborator with strong structural overlap.
• KHAN Technology Transfer Fund II: Early-stage life sciences and tech-transfer fund that co-invested alongside NRW.Venture in iDEL Therapeutics. Comparable in early-stage biotech focus and the role of co-investor in syndicates with German regional public funds.
• High-Tech Gründerfonds (HTGF): Germany's leading early-stage technology VC, backed by federal and corporate investors including KfW Capital. Comparable in stage (seed/Series A), sector breadth (tech, biotech, deep tech), and the role of co-investing alongside NRW.Venture-style regional public-bank funds.
• BiomedVC: Biotech-focused venture capital firm that led iDEL Therapeutics' seed round with NRW.Venture as co-investor. Comparable as a specialist sector VC operating in the same German biotech ecosystem and frequently syndicating with regional public-bank funds.

Regional players

• IBB Ventures (Investitionsbank Berlin): Venture capital arm of Berlin's state-owned development bank IBB. Highly comparable structurally — public-bank VC arm with regional investment mandate — but serves the Berlin/Brandenburg ecosystem rather than NRW, so competes for German state-backed VC talent and deal flow.

Broad incumbents

• NRW.BANK: Parent institution of NRW.Venture. Not a peer in the strict sense but is the broader incumbent that hosts NRW.Venture and provides capital, regulatory backing, and operational infrastructure — useful for understanding scale and competitive positioning relative to other German state development banks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/channel/UCo2VZ2trTdilIG56P9ROnvA
• LinkedInlinkedin.com/company/nrw-bank
• Instagraminstagram.com/nrw.bank
• Xx.com/NRWBANK

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NRW.Venture